Design, synthesis, and anti-proliferative evaluation of new quinazolin-4(3H)-ones as potential VEGFR-2 inhibitors.

Bioorganic & Medicinal Chemistry
Khaled El-AdlIbrahim H Eissa

Abstract

Inhibiting VEGFR-2 has been set up as a therapeutic strategy for treatment of cancer. Thus, nineteen new quinazoline-4(3H)-one derivatives were designed and synthesized. Preliminary cytotoxicity studies of the synthesized compounds were evaluated against three human cancer cell lines (HepG-2, MCF-7 and HCT-116) using MTT assay method. Doxorubicin and sorafenib were used as positive controls. Five compounds were found to have promising cytotoxic activities against all cell lines. Compound 16f, containing a 2-chloro-5-nitrophenyl group, has emerged as the most active member. It was approximately 4.39-, 5.73- and 1.96-fold more active than doxorubicin and 3.88-, 5.59- and 1.84-fold more active than sorafenib against HepG2, HCT-116 and MCF-7 cells, respectively. The most active cytotoxic agents were further evaluated in vitro for their VEGFR-2 inhibitory activities. The results of in vitro VEGFR-2 inhibition were consistent with that of the cytotoxicity data. Molecular docking of these compounds into the kinase domain, moreover, supported the results.

References

Dec 24, 1997·The Journal of Pharmacy and Pharmacology·M I ThabrewI G McFarlane
Feb 26, 2000·Carcinogenesis·R S Kerbel
Apr 14, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J C LeeS M Huang
Feb 7, 2006·Bioorganic & Medicinal Chemistry Letters·Wei-xiao HuXi Wen
Jun 20, 2006·Nature Chemical Biology·Yi Liu, Nathanael S Gray
Sep 19, 2006·Bioorganic & Medicinal Chemistry Letters·Shenlin HuangLee M Greenberger
Jan 14, 2009·Journal of Molecular Graphics & Modelling·Qing-Qing XieSheng-Yong Yang
Sep 28, 2010·European Journal of Medicinal Chemistry·Kyungik LeeYangmee Kim
Oct 15, 2010·Bioorganic & Medicinal Chemistry Letters·Ying YangHai-Liang Zhu
Mar 1, 2011·Bioorganic & Medicinal Chemistry Letters·Antonio GarofaloPatrick Depreux
Jun 15, 2012·Archiv der Pharmazie·Awatef A FaragSamir Y Abbas
Feb 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lipika GoyalAndrew X Zhu
Nov 26, 2013·European Journal of Medicinal Chemistry·Maria Letícia de Castro BarbosaEliezer J Barreiro
Jan 13, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ilary RuscitoPierluigi Benedetti Panici
May 16, 2017·European Journal of Medicinal Chemistry·Mona A AbdullazizHoda I El Diwani
Jul 13, 2017·Anti-cancer Agents in Medicinal Chemistry·Ibrahim H EissaAhmed S A Youssef
Sep 1, 2017·BMC Cancer·Zhiyong LiuBaocun Sun
Jan 14, 2020·International Journal of Biological Sciences·Mengya ZhongGuohong Zhuang
Mar 3, 2020·Frontiers in Cell and Developmental Biology·Haiyu WangZujiang Yu

❮ Previous
Next ❯

Citations

Feb 17, 2021·Journal of Enzyme Inhibition and Medicinal Chemistry·Mohamed HagrasIbrahim H Eissa
Apr 4, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Nadipolla Naresh ReddyPuchakayala Muralidhar Reddy
Oct 2, 2021·Archiv der Pharmazie·Khaled El-AdlIbrahim H Eissa

❮ Previous
Next ❯

Related Concepts